PortalPublikationenTreatment with bevacizumab and FOLFOXIRI in patients with ad...

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.

Standard

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. / Stein, Alexander; Glockzin, Gabriel; Wienke, Andreas; Arnold, Dirk; Edelmann, Thomas; Hildebrandt, Bert; Hollerbach, Stephan; Illerhaus, Gerald; Königsrainer, Alfred; Richter, Michael; Schlitt, Hans J; Schmoll, Hans-Joachim.

in: BMC CANCER, Jahrgang 12, 2012, S. 356.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stein, A, Glockzin, G, Wienke, A, Arnold, D, Edelmann, T, Hildebrandt, B, Hollerbach, S, Illerhaus, G, Königsrainer, A, Richter, M, Schlitt, HJ & Schmoll, H-J 2012, 'Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.', BMC CANCER, Jg. 12, S. 356. https://doi.org/10.1186/1471-2407-12-356

APA

Stein, A., Glockzin, G., Wienke, A., Arnold, D., Edelmann, T., Hildebrandt, B., Hollerbach, S., Illerhaus, G., Königsrainer, A., Richter, M., Schlitt, H. J., & Schmoll, H-J. (2012). Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC CANCER, 12, 356. https://doi.org/10.1186/1471-2407-12-356

Vancouver

Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC CANCER. 2012;12:356. https://doi.org/10.1186/1471-2407-12-356

Bibtex

@article{24a44336f5ce42a49fdb9ba82da32d6a,
title = "Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.",
abstract = "More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis.",
author = "Alexander Stein and Gabriel Glockzin and Andreas Wienke and Dirk Arnold and Thomas Edelmann and Bert Hildebrandt and Stephan Hollerbach and Gerald Illerhaus and Alfred K{\"o}nigsrainer and Michael Richter and Schlitt, {Hans J} and Hans-Joachim Schmoll",
year = "2012",
doi = "10.1186/1471-2407-12-356",
language = "English",
volume = "12",
pages = "356",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.

AU - Stein, Alexander

AU - Glockzin, Gabriel

AU - Wienke, Andreas

AU - Arnold, Dirk

AU - Edelmann, Thomas

AU - Hildebrandt, Bert

AU - Hollerbach, Stephan

AU - Illerhaus, Gerald

AU - Königsrainer, Alfred

AU - Richter, Michael

AU - Schlitt, Hans J

AU - Schmoll, Hans-Joachim

PY - 2012

Y1 - 2012

N2 - More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis.

AB - More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis.

U2 - 10.1186/1471-2407-12-356

DO - 10.1186/1471-2407-12-356

M3 - SCORING: Journal article

VL - 12

SP - 356

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

ER -